

LIVERPOOL REVIEWS AND IMPLEMENTATION GROUP (LRiG)

Clopidogrel and modified-release
dipyridamole for the prevention of
occlusive vascular events (review of
Technology Appraisal No. 90)

ADDENDUM 4

This report was commissioned by
the NIHR HTA Programme as
project number 08/97/01

Completed: June 23rd 2010

DOES NOT CONTAIN IN CONFIDENCE DATA



UNIVERSITY OF
LIVERPOOL

LIVERPOOL
REVIEWS AND
IMPLEMENTATION
GROUP

A MEMBER OF THE RUSSELL GROUP

ADDENDUM 4: CORRECTED TABLE 6-40

Introduction

Please find overleaf the correct version of Table 6-40. This version includes correction of an identified anomaly. The source of the problem is directly traceable to a simple transcription error in transferring the spreadsheet results into the Word table (i.e. all of the calculated results are unaffected).

Table 6-40 Deterministic results from AG model for treatment of the 'IS only' population with intolerance to ASA

CLOP price	TA90 status	Strategy			Costs					Utility	Incremental analysis 1			Incremental analysis 2			Incremental analysis vs. 3		
		Tx 1	Tx 2	Tx 3	APT	Events	Cont. care	AE	Total	QALYs	IQ	IC	ICER	IQ	IC	ICER	IQ	IC	ICER
ASA intolerant																			
Full	MRD	None	None	None	£164	£9,365	£25,697	£47	£35,273	6.806									
	MRD	Clop	None	None	£3,433	£7,406	£26,954	£186	£37,979	7.463	0.657	£2,705	£4,120	0.288	£1,457	£5,066			
	MRD	MRD	None	None	£777	£8,779	£26,744	£223	£36,522	7.175	0.369	£1,248	£3,384						
	MRD	Clop	MRD	None	£3,639	£7,487	£27,328	£245	£38,698	7.534	0.728	£3,425	£4,707	0.359	£2,177	£6,069	0.071	£719	£10,139
	MRD	MRD	Clop	None	£1,933	£8,435	£27,062	£277	£37,706	7.335	0.528	£2,432	£4,605	0.159	£1,184	£7,435	-0.128	-£273	£2,126
Full	Not used	None	None	None	£0	£8,887	£26,568	£0	£35,455	6.956									
	Not used	Clop	None	None	£3,470	£7,010	£27,409	£158	£38,047	7.547	0.591	£2,592	£4,384	0.248	£1,143	£4,604			
	Not used	MRD	None	None	£670	£8,404	£27,638	£192	£36,905	7.299	0.343	£1,450	£4,225						
	Not used	Clop	MRD	None	£3,650	£7,099	£27,705	£209	£38,664	7.633	0.678	£3,209	£4,736	0.334	£1,759	£5,259	0.086	£616	£7,142
	Not used	MRD	Clop	None	£1,747	£8,029	£27,752	£241	£37,768	7.462	0.506	£2,313	£4,570	0.163	£864	£5,296	-0.085	-£279	£3,278
Generic	MRD	None	None	None	£164	£9,365	£25,697	£47	£35,273	6.806									
	MRD	Clop	None	None	£1,116	£7,406	£26,954	£186	£35,662	7.463	0.657	£388	£591						
	MRD	MRD	None	None	£777	£8,779	£26,744	£223	£36,522	7.175	0.369	£1,248	£3,384	-0.288	£860	Dom			
	MRD	Clop	MRD	None	£1,321	£7,487	£27,328	£245	£36,381	7.534	0.728	£1,108	£1,522	0.071	£719	£10,139			
	MRD	MRD	Clop	None	£1,127	£8,435	£27,062	£277	£36,900	7.335	0.528	£1,627	£3,080	-0.128	£1,239	Dom			
Generic	Not used	None	None	None	£0	£8,887	£26,568	£0	£35,455	6.956									
	Not used	Clop	None	None	£1,041	£7,010	£27,409	£158	£35,618	7.547	0.591	£163	£275						
	Not used	MRD	None	None	£670	£8,404	£27,638	£192	£36,905	7.299	0.343	£1,450	£4,225	-0.248	£1,287	Dom			
	Not used	Clop	MRD	None	£1,221	£7,099	£27,705	£209	£36,234	7.633	0.678	£779	£1,150	0.086	£616	£7,142			
	Not used	MRD	Clop	None	£993	£8,029	£27,752	£241	£37,015	7.462	0.506	£1,560	£3,080	-0.085	£1,397	Dom			

IC, IQ = incremental cost & QALYs, ICER = incremental cost-effectiveness ratio, Dom = dominated, ICER in **bold** = strategy on cost-effectiveness frontier, Cont. care = continuing care costs